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In principle, bone marrow transplantation
should offer effective treatment for disor-
ders originating from defects in mesenchy-
mal stem cells. Results with the bone dis-
ease osteogenesis imperfecta support this
hypothesis, although the rate of clinical im-
provement seen early after transplantation
does not persist long term, raising ques-
tions as to the regenerative capacity of the
donor-derived mesenchymal progenitors.
We therefore studied the kinetics and histo-
logic/anatomic pattern of osteopoietic en-
graftment after transplantation of GFP-
expressing nonadherent marrow cells in
mice. Serial tracking of donor-derived GFP
cells over 52 weeks showed abundant clus-
ters of donor-derived osteoblasts/osteo-
cytes in the epiphysis and metaphysis but
not the diaphysis, a distribution that paral-
leled the sites of initial hematopoietic en-
graftment. Osteopoietic chimerism de-
creased from approximately 30% to 10% by
24 weeks after transplantation, declining to
negligible levels thereafter. Secondary trans-
plantation studies provided evidence for a
self-renewing osteopoietic stem cell in the
marrow graft. We conclude that a transplant-
able, primitive, self-renewing osteopoietic
cell within the nonadherent marrow cell
population engrafts in an endosteal niche,
like hematopoietic stem cells, and regener-
ates a significant fraction of all bone cells.
The lack of durable donor-derived osteopoi-
esis may reflect an intrinsic genetic pro-
gram or exogenous environmental signal-
ing that suppresses the differentiation
capacity of the donor stem cells. (Blood.
2008;111:4386-4391)
© 2008 by The American Society of Hematology
Introduction
There are no obvious reasons why bone marrow transplantation
(BMT) could not be used to correct a far greater range of stem-cell
disorders than is commonly reported. This potential resides in the
heterogeneity of the bone marrow cell population, which comprises
precursors of several different tissues other than blood, including
bone, cartilage, and muscle. Indeed, in animal models and clinical
studies, transplanted marrow-derived mesenchymal cells migrate
to and become incorporated into the recipient’s bone and muscle,1-7
suggesting a therapeutic capacity for these cells.
Prompted by encouraging preclinical studies,8,9 we undertook a
series of clinical trials of allogeneic bone marrow cell therapy as
treatment for children with severe osteogenesis imperfecta (OI),2,3,10 a
genetic disorder in which generalized osteopenia leads to bony deformi-
ties, excessive bone fragility with fracturing, and short stature. The
underlying defect is a mutation in one of the 2 genes encoding type
I collagen, the primary structural protein of bone. After transplantation
of unmanipulated whole bone marrow, we demonstrated marked
improvement in total body mineral content and the microscopic
structure of abnormal bone that were associated with accelerated linear
growth and decreased fracture rates.2,10 Similarly, after transplantation of
isolated donor-derived marrow mesenchymal stromal cells (MSCs) in
the same patients, we observed a second phase of striking accelerated
linear growth.3 In all instances, however, the observed acceleration of
growth was not sustained with time after transplantation.
Thus, the inability of BMT to produce a sustained rate of
improvement in the abnormalities of OI in children could be due
either to engraftment of an osteopoietic progenitor with limited
self-renewal and differentiation capacity or to engraftment of an
osteopoietic stem cell with robust self-renewal properties that are subject
to intrinsic or environmental regulatory mechanisms which prevent
sustained therapeutic levels of donor-derived osteopoiesis. To address
these possibilities, we studied the kinetics, histologic pattern, and
anatomic distribution of osteopoietic donor cells after transplantation of
nonadherent marrow cells in mice. Our selection of the nonadherent cell
population was based on its more robust transplantable osteoprogenitor
activity, compared with that of MSCs. Our findings, that the primary
source of donor cell–derived osteopoiesis in this model is indeed a
primitive cell with self-renewing capacity, but that the extent of
osteoblast repopulating activity is limited by mechanisms that regulate
the differentiation of these stem cells.
Methods
Transduction and transplantation of murine marrow cells
Donor and recipient (male and female, respectively; 6 to 8 weeks old)
FVB/N mice (The Jackson Laboratory, Bar Harbor, ME) were maintained
in the animal facility at St Jude Children’s Research Hospital under
standard conditions. Donor marrow cells were harvested, transduced with a
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green fluorescent protein (GFP)–expressing retroviral vector, and trans-
planted into lethally irradiated (1125 cGy) recipient mice as previously
described.5 Secondary transplantation studies used GFP-transgenic mice11
as primary donors. All animal protocols were approved by the Institutional
Animal Use and Care Committee.
Immunohistochemical staining
Formalin-fixed, decalcified, and paraffin-embedded sections were stained
with standard hematoxylin and eosin. (H&E; Sigma-Aldrich, St Louis,
MO). Single and double immunohistochemical analyses were performed
with rabbit anti-GFP antibody (1:300; Invitrogen, Carlsbad, CA), rabbit
anti-collagen I (Col I) antibody (1:100; Chemicon International, Temecula,
CA), and rabbit anti-osteocalcin (1:100; Cosmo Bio, Tokyo, Japan), with a
goat anti-rabbit biotinylated secondary antibody (1:200; Vector Laborato-
ries, Burlingame, CA) as previously described.5 Horseradish peroxidase
was visualized with both NOVARed (red) and diaminobenzidine salts
(Nickel-DAB, black; Vector Laboratories).
All slides were counterstained with Harris hematoxylin (Surgipath
Medical Industries, Richmond, IL). Negative control specimens were
sections taken from animals given transplants of mock-transduced marrow
cells and immunostained with the anti-GFP antibody. As an additional
negative control, bone sections from the experimental mice were immuno-
stained with an isotypic primary antibody (Vector Laboratories). Back-
ground staining was not apparent in any of the cases.
Microscopy
Stained slides were examined on a Nikon E800 (Nikon, Melville, NY) with
either a 10/0.3 NA or a 40/0.95 NA dry objective. Photomicrographs
were acquired using the attached Nikon DXM1200 color camera and Nikon
ACT-1 Version 2.11 software (Nikon, Melville, NY). Images were cropped
and labeled using Photoshop 7.0 and Illustrator 10.0 (Adobe Systems,
San Jose, CA).
Flow cytometry
Peripheral blood and bone marrow were analyzed for GFP expression by
flow cytometry as previously described.12
Statistics
Analyses were performed with the Excel 2003 program (Microsoft,
Redmond, Washington) or Prism, version 4 (GraphPad, San Diego, CA).
A 2-tailed P value of .05 or less from the Student t test was considered
statistically significant.
Results
Kinetics and histologic pattern of osteopoietic engraftment
To more accurately define the kinetics of osteopoietic engraftment
after BMT, we used our murine transplantation model, in which we
previously demonstrated the capacity of nonadherent bone marrow
cells to engraft in bone.5 After transplanting lethally irradiated
FVB/N recipient mice with 2 106 nonadherent bone marrow
cells (FVB/N donors), transduced with a GFP-expressing retroviral
vector, we used immunohistochemical staining to identify donor
cells. Relatively large, cuboidal cells, often showing abundant
cytoplasm and eccentrically placed nuclei, distributed along the
endosteal surface were considered to be osteoblasts, while solitary,
stellate-shaped cells within the lacunae of bone were regarded as
osteocytes. Double staining of representative sections of bone at
4 weeks after transplantation demonstrated that these bone cells
coexpressed GFP and osteocalcin (Figure 1A), or GFP and collagen
I (Figure 1B), confirming their identity as osteoblasts and osteocytes.
We then traced the fate of transplanted, GFP-transduced nonad-
herent marrow cells in the osteoblast and osteocyte niches of bone
(Figures 2,3). At 2 weeks, 25.5% plus or minus 7.8% (mean SD)
of the osteoblasts in the metaphysis and epiphysis were of donor
origin, while only rare donor-derived osteoblasts ( 1%) were
found in the diaphysis (Figure 2). The donor cells appeared as
several small clusters of GFP cells along the endosteal surface,
invariably adjacent to GFP hematopoietic cells within the marrow
space. In contrast to the substantial donor contribution to the
osteoblast population, only 4.6% plus or minus 1.7% of osteocytes
in the metaphysis and epiphysis, and none in the diaphysis, were
donor derived at 2 weeks after transplantation. As with the
donor-derived osteoblasts, these osteocytes were arranged as
clusters within the trabecular bone in close proximity to the
endosteal surface.
At 4 weeks after transplantation, the proportion of donor-
derived osteoblasts had decreased to 21.7% plus or minus 8.1%
(Figure 3). The cells were arranged as clusters without GFP host
cells, although numerous GFP cells were seen between the
clustered (GFP) donor osteoblasts (Figure 2). There was an
increased proportion of donor derived osteocytes in clusters of
10 to 15 GFP cells each, accounting for 12.2% plus or minus 7.5%
of all osteocytes in the metaphysis and epiphysis. The donor cells
were most often found toward the middle of the trabeculae in the
histologic sections. GFP cells were not detectable in the diaphysis.
The contribution of donor-derived cells to the osteoblast
compartment of the metaphysis and epiphysis steadily declined
from the peak at 2 weeks to 16.1% plus or minus 8.1% at 6 weeks
and 1.5% plus or minus 1.3% at 24 weeks after transplantation. By
1 year, donor cells were minimally detectable in bone (0.3% 
0.3%). By contrast, the donor fraction of osteocytes rose from 2 to
4 weeks, remaining statistically stable from 6 weeks (9.2% 
3.5%) to 24 weeks (9.6%  1.0%). Donor osteocytes were rarely
seen (0.6% 0.4%) at 1 year after transplantation (Figure 3).
Kinetics and histologic pattern of hematopoietic engraftment
If, as we propose,5 the transplantable osteopoietic cells are derived
from a common nonadherent hematopoietic-osteopoietic progeni-
tor, what might account for the lack of durable osteopoietic
engraftment in our murine model? One explanation might be that
the donor cells were defective in their long-term regenerative
capacity overall.
To test this prediction, we first analyzed the contribution of
GFP cells to subsets of hematopoietic cells in the peripheral blood
using flow cytometry. From 2 to 8 weeks after transplantation, the
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Figure 1. Nonadherent donor bone marrow cells engraft as osteoblasts and
osteocytes after transplantation. (A) Representative photomicrograph of a bone/
bone marrow section taken from a mouse after nonadherent marrow cell transplanta-
tion double stained with anti-GFP (black) and antiosteocalcin (red) antibodies.
Several double-positive donor osteoblasts are distributed along the surface of
endosteal bone, with a donor (GFP) osteocyte embedded in bone. Osteocalcin-
expressing host cells (H; red stain without GFP) are indicated by arrows.
(B) Bone/bone marrow section double stained with anti-GFP (black) and anti-
collagen l (red) antibodies. Donor osteoblasts and osteocytes were detected by
red/black colocalization. Collagen-expressing host osteocytes (H) are indicated by
arrows. (C) Control bone section from a mouse transplanted with nontransduced
nonadherent bone marrow cells and stained with anti-GFP and isotype control
antibodies. Original magnification for all panels, 1600 (400 optical, 4 digital).
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proportion of leukocytes, erythrocytes, and platelets increased
substantially to 82.7% plus or minus 3.4%, 78.0% plus or minus
1.2%, and 76.1% plus or minus 2.9%, respectively (Figure 4A).
Long-term analysis showed that the overall contribution of donor
cells to blood increased from 8 weeks to 24 weeks (79.0% 3.7%
to 93.3%  8.1%) remaining stable at 52 weeks (Figure 4B). The
total marrow cellularity, determined by histologic examination of
sequential bone marrow sections, increased from 49.6% plus or
minus 12.7% at 2 weeks to 90% plus or minus 4.0% at 8 weeks,
remaining stable at 52 weeks (93.3%  2.5%). The fraction of
GFP bone marrow cells was about 98% at 2 weeks, 82% to 84% at
4 to 8 weeks, and more than 95% at 24 weeks, a level that was
maintained through 52 weeks (Figure 4C).
At 2 weeks after transplantation, the total marrow and GFP
marrow cells preferentially localized to the trabecular bone of the
metaphysis and epiphysis (cellularity, 77.4%  16.8%) as com-
pared with the diaphysis (cellularity, 30.1% plus or minus 27.1%;
P  .001; Figure 5A-D). The marrow cells appeared in clusters that
gave a patchy appearance to engraftment. Although several groups
of donor (GFP) marrow cells were found along a bone surface
lacking donor (GFP) osteopoietic cells, all areas of donor
osteopoietic engraftment bordered donor marrow cell clusters
(Figure 5E). From 4 to 52 weeks after transplantation, there was no
evidence of anatomic variation of the total and GFP marrow
cellularity (P  .05). Thus, these mice exhibit an expected pattern
of hematopoietic reconstitution after transplantation of GFP-
marked nonadherent cells. Together, these data suggest that hema-
topoietic stem cell niches capable of engrafting transplanted, or
circulating, hematopoietic stem cells reside in the metaphysis and
epiphysis, coincident with the anatomic distribution of donor-
derived osteopoietic cells.
Secondary bone marrow transplantation
The above results led us to consider that osteopoietic engraftment
might be a time-limited process in our model due to reconstitution
from a short-term osteopoietic stem cell distinct from the long-term
hematopoietic stem cell that gave rise to normal hematopoietic
reconstitution of bone marrow. If so, the putative osteopoietic cell
would be expected to have limited self-renewal capacity, rendering
it incapable of maintaining a stem cell pool, in contrast to stem cells
with of long-term repopulating activity. This possibility was
assessed by studying osteopoietic engraftment animals that under-
went serial transplantation.
Lethally irradiated normal FVB/N mice (n 3) received trans-
plants with 2 106 nonadherent bone marrow cells harvested from
a GFP-transgenic mouse11 (FVB/N genetic background). At
8 weeks after transplantation, the bone marrow was more than 98%
donor derived (GFP cells) by flow cytometric analysis, and the
bone cells (osteoblasts and osteocytes) were 7.9% plus or minus
4.2% donor-derived (GFP) by immunohistochemical staining and
microscopic examination (Figure 6). Bone marrow cells (98%
GFP), harvested from the primary recipients at 8 weeks after
transplantation, were transplanted into lethally irradiated secondary
recipients (5 106 cells/mouse; n 10 mice). At 3 weeks later,
the peripheral blood (80.1% 10.1%) and bone marrow (84.5%
8.2%) were predominately from donor cells. Most importantly,
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Figure 2. Patterns of bone engraftment with increasing time after transplanta-
tion of nonadherent bone marrow cells. Sections taken at 2 to 52 weeks after
transplantation from different regions of bone (Bo) and bone marrow (BM) were
stained with anti-GFP antibody (red). At 2 weeks, GFP osteoblasts (arrows)
engrafted as clusters next to host (GFP) osteoblasts in the epiphysis and in the
metaphysis, while in the diaphysis the osteoblasts remained almost exclusively host
derived. Beginning at 4 weeks, GFP osteocytes (dashed arrows) were consistently
detected in both the metaphysis and epiphysis. At 8 weeks, in the metaphysis, in
particular, Bo-embedded GFP cells could be identified under the growth plate (GP)
as cell clusters. Again, the donor contribution was virtually undetectable in the
diaphysis. At 24 weeks, a similar pattern of donor-derived osteopoiesis was evident.
By 52 weeks, neither donor Bo nor BM contained GFP osteoblasts or osteocytes.
The bottom row consists of photomicrographs of control (CTL) Bo/BM sections from a
mouse that received a transplant of untransduced cells that were stained with
anti-GFP antibody. Original magnification of all panels, 400.
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Figure 3. Kinetics of bone engraftment after transplantation. Robust GFP
osteoblast engraftment was detected at 2 and 4 weeks after transplantation with
significant declines thereafter: 6 weeks (P  .02), 8 weeks (P  .04), 24 weeks
(P  .01). GFP osteocyte engraftment showed a different kinetic profile character-
ized by a significant increase at 4 weeks (P  .04), a plateau phase and a significant
decrease to a negligible level at 52 weeks (P  .004). To quantify the engraftment of
donor GFP  cells in bone, we scored 20 random 400 fields in both the epiphysis
and the metaphysis of 10 bone sections taken from each mouse at different times
after transplantation (n  4 mice per group). Experiments were performed in
triplicate. The reported values are mean (SD) percentages of GFP cells per 400
microscopic field.
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donor cell osteopoiesis accounted for 7.5% plus or minus 1.3% of
the bone cells in the epiphysis and metaphysis. These data suggest
that the primitive transplantable marrow cells responsible for the
restoration of osteopoiesis also undergo self-renewal, a primary
characteristic of stem cells with multilineage potential.
Discussion
The identification of the hematopoietic stem-cell niche13,14 has
directed much effort toward understanding the mechanism(s) by
which stem cells engraft and differentiate in the marrow microenvi-
ronment after transplantation. This question is especially intriguing
in the case of bone disorders, as little is known about the nature of
the transplantable marrow osteoprogenitor cells and curiously, all
of the available data indicate early engraftment of osteopoietic cells
but a lack of long-term repopulating capacity.1,5,15 In this report, we
provide key elements needed to understand these critical issues and
to begin to devise alternative means to ensure durable engraftment
of osteopoietic cells.
In our murine model, clusters of GFP osteoblasts and osteo-
cytes were found in the epiphysis and metaphysis of the long bones
with negligible concentrations of donor cells in the diaphysis. This
pattern of osteopoietic engraftment paralleled hematopoietic seed-
ing early after BMT, consistent with previous reports16 suggesting
that the endosteal stem-cell niche17-19 resides in the metaphysis and
epiphysis as opposed to the diaphysis. Moreover, bone growth in
the diaphysis of mice is predominantly due to periosteal matrix
appostion, in contrast to endosteal bone formation of the metaphy-
sis.20 Thus, endosteum of the metaphysis and epiphysis appears to
harbor the niche for both hematopoietic stem cells and endogenous
primitive osteoprogenitors, and perhaps a bipotential hematopoietic-
osteopoietic stem cell.5 This constellation of engraftment and the
anatomic distribution of endogenous progenitors support a close
functional and developmental relationship between blood and
bone. Interestingly, Onyia et al compared the transplantation
efficiency of adherent MSCs directly injected into the metaphysis
and the diaphysis, and found a complete lack of engraftment in the
diaphysis, in contrast to the high level seen in the metaphysis,21
suggesting that ex vivo expanded MSCs may also engraft in this
osteopoietic stem-cell niche. The low level of MSC engraftment in
the marrow seen by these authors and others8,22,23 after systemic
infusion may be due to the lack of appropriate marrow homing
signals. In our studies, the transplantable osteopoietic cells do seem
to home to the marrow space and engraft in specific sites.
Moreover, we have previously shown that engraftment of the
transplantable marrow osteoprogenitor is saturable24; thus, direct
intrafemoral injection of our nonadherent marrow cells would
likely yield results similar to what we have observed after
intravenous infusion.
The robust level of donor-derived osteopoiesis observed early
after transplantation in our murine model, followed by decreasing
donor osteopoietic chimerism over time, corresponds closely to the
abbreviated course and temporary measurable osteopoietic engraft-
ment in children with severe OI. This relationship supports our
hypothesis that the clinical improvement secured early in patients
with OI arose from the engraftment and differentiation of donor-
derived marrow cells and validates further use of the mouse to test
clinically relevant predictions regarding the fate of transplantable
nonadherent cells in the bone and marrow microenvironments.
Moreover, early robust osteopoietic engraftment with early func-
tional improvement of bone followed by decreasing donor osteopoi-
etic chimerism and waning of bone function seems to be a general
characteristic of osteopoietic engraftment by transplanted marrow
cells, and not limited to specific diseases. This profile was found in
normal mice previously,8 in normal mice in this report, in children
with severe OI, and in a child who underwent bone marrow
transplantation as therapy for infantile hypophosphatasia.25 Finally,
transplantation of bone marrow cells in a murine model of a severe
genetically linked osteoporosis was followed by rapid amelioration
of the pathologic phenotype with a slow reversion to the pretreat-
ment status over time.26,27
How, then, does one explain high levels of osteopoietic
engraftment early after BMT with diminishing osteopoietic chimer-
ism over time? Bone is a dynamic tissue undergoing continuous
remodeling with high cell and matrix turnover. The life span of a
murine osteoblast is only 10 to 20 days,28,29 and both osteoblasts
and osteocytes show high rates of apoptosis,19,30 which are linked
to repopulation by primitive osteoprogenitors and preosteoblasts
during physiologic bone turnover.31 Thus, the progressive decrease
of donor-derived osteopoiesis likely reflects the normal physiologic
turnover of osteoblasts and osteocytes, but this mechanism does not
explain the lack of newly differentiated osteoblasts from the
engrafted donor primitive cells.
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Figure 4. Nonadherent bone marrow cells can produce stable hematopoietic
engraftment. (A) GFP expression by white blood cells (WBC), red blood cells (RBC),
and platelets (PLT) assessed by flow cytometry with the whole peripheral blood
analyses. The findings are reported as mean (SD) percentages of GFP cells
representing each of the 3 hematopoietic lineages. Values for all lineages were
significantly increased at 24 weeks (WBC, P  .001; RBC, P  .03; PLT, P  .008)
compared with 2 weeks, becoming stable thereafter. (B) Flow cytometric analysis of
GFP expression in whole peripheral blood (PB) collected from the mice that
underwent transplantation (n  4 per group) at increasing times after transplantation.
The findings are reported as mean (SD) percentages of GFP cells. (C) GFP
expression in bone marrow assessed at different times after transplantation. We
scored 20 randomly selected 400 fields in representative sections from each mouse
(n  4 mice per group). The values were derived from immunohistochemical
analyses of bone/bone marrow sections stained with anti-GFP antibody and are
expressed as mean (SD) percentages of GFP cells in each microscopic field. All
experiments were performed in triplicate.
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One possibility is that the donor-derived osteoblasts do not
differentiate according to known physiologic pathways. Label-
ing transplantable marrow cells with a GFP-encoding retroviral
vector afforded us a unique opportunity to track the fate of
undifferentiated cells in the marrow microenvironment along
the osteopoietic differentiation pathway after transplantation,
because GFP expression in our system is not affected by cell
differentiation.12 Evidence that donor-derived osteopoietic cells
were developing in the correct pathways was provided by the
1:5 ratio of donor-derived osteocytes to osteoblasts seen at
2 weeks after transplantation, which is consistent with the
finding that approximately 1 of 5 osteoblasts gives rise to an
osteocyte.31 The osteoblasts that do not give rise to osteocytes
secrete bone matrix proteins,31 contribute to the hematopoietic
stem cell niche,13 or assume a more flattened morphology,
becoming quiescent progenitors within a functional reservoir of
osteogenic cells residing within the bone lining compartment.32
Importantly, histologic sections taken at serial time points
suggest that the donor-derived cells transitioned from the
endosteal compartment to bone consistent with the in vivo
conversion of osteoblasts to osteocytes. However, the depth of
the osteocytes embedded within trabeculae could not be accu-
rately assessed in our 2D images of the 3D bony structures.
Nonetheless, by all other criteria, the engrafted donor cells
derived from either retrovirally transduced or transgenic donor
cells appear to have differentiated along established pathways.
This conclusion is supported by the exclusive presence of
donor-derived osteocytes at locations also occupied by donor-
derived osteoblasts.
It is certainly reasonable to consider that the transplantable
marrow osteoprogenitor identified in this study lacks long-term
self-renewing capacity and thus was unable to sustain robust
engraftment beyond 6 months after transplantation. We reject
this possibility on the basis of our secondary transplantation
data, which show statistically identical levels of osteopoietic
engraftment in primary and secondary recipients. Although the
analysis of the secondary recipients at 3 weeks after transplanta-
tion was too early to allow a valid assessment of hematopoietic
stem cell self-renewal, the data in Figure 3 indicate that this
interval provides an ideal time point for evaluating osteopoietic
engraftment. Thus, the results of our secondary transplantation
experiments lend compelling support to the hypothesis that a
long-term self-renewing osteoprogenitor resides in the transplant-
able population of nonadherent marrow cells. Its identity is most
compatible with the bipotent hematopoietic-osteopoietic stem
cell that we have previously proposed.5 Hence, after the initial
burst of repopulating activity by donor-derived stem cells
leading to full hematopoietic regeneration and partial osteopoi-
etic chimerism, intrinsic genetic programs or signals from the
microenvironment could modulate the differentiation of
transplanted stem cells to osteoblasts so that only a low level
of donor-derived osteopoiesis is maintained. If this hypothesis
is correct, the future challenge will be to identify the mole-
cular and cellular regulatory signals responsible for post-
transplantation osteopoiesis and devise methods that could
be used to manipulate multipotent stem cells toward the
osteopoietic lineage.
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Figure 5. Nonadherent bone marrow cells engraft preferentially in
metaphysis and epiphysis in the early regenerative phases after
BMT. (A) Photomicrograph of a bone (Bo)/bone marrow (BM) section
taken from the epiphysis of a mouse that underwent transplantation
killed at 2 weeks after transplantation and stained with anti-GFP
antibody (red). Original magnification, 100. (B) Low level of GFP
cells engrafted as clusters in the diaphysis, mainly in close proximity to
the endosteal bone surface (asterisk). (C) Section of bone from a
mouse that received a transplant of untransduced nonadherent mar-
row cells and stained with anti-GFP antibody (negative control).
(D) Comparison of GFP engraftment in the diaphysis versus the
metaphysis/epiphysis at 2 weeks after transplantation. A total of
20 random 400 fields of bone sections from each of 4 mice were
studied. The reported values are mean (SD) percentages of GFP
cells per field. The difference in engraftment is highly significant
(P  .001). (E) Photomicrograph of a bone (Bo)/bone marrow (BM)
section taken from the metaphysis of a transplanted mouse killed at
2 days after transplantation and stained with anti-GFP antibody
(red). The cluster of early osteopoietic engraftment (arrows) is
adjacent to donor (GFP) hematopoietic cells (asterisk). Original
magnification, 400.
Figure 6. The osteopoietic capacity of nonadherent bone marrow cells is
preserved in secondary recipients. Immunohistochemical identification of donor-
derived bone cells (arrows) in primary (A) and secondary (B) recipients.
(C) Section of bone from a mouse that received a transplant of untransduced
nonadherent marrow cells and stained with anti-GFP antibody (negative control).
(D) Comparison of the percentages of donor-derived osteopoiesis in primary
(n  3 mice) versus secondary (n  10 mice) recipients. The reported values are
mean ( SD) percentages of GFP cells. Bone engraftment was quantified as
described in Figure 3; P  .05.
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cell with a limited regenerative contribution after transplantation
derived osteopoiesis originates from a self-renewing stem−Donor cell
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